Research programme: cognitive disorder gene therapy - Agilis Biotherapeutics/University of South Florida

Drug Profile

Research programme: cognitive disorder gene therapy - Agilis Biotherapeutics/University of South Florida

Alternative Names: AGIL-AS - Agilis/University of South Florida; Angelman syndrome gene therapy - Agilis/University of South Florida; Angelman Syndrome Therapeutics - Agilis/USF; AS gene therapy - Agilis/University of South Florida; Reelin based therapy - Agilis/University of South Florida; Reelin-based gene therapy - Agilis/University of South Florida; UBE3a therapy - Agilis/University of South Florida

Latest Information Update: 27 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of South Florida
  • Developer Agilis Biotherapeutics; University of South Florida
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Angelman syndrome
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Angelman syndrome
  • Research Fragile X syndrome

Most Recent Events

  • 20 Oct 2017 Pharmacodynamics data from preclinical studies in Angelman syndrome released by Agilis Biotherapeutics
  • 03 Oct 2017 Agilis Biotherapeutics plans a clinical trial for Angelman syndrome in 2019
  • 04 May 2016 Research programme: cognitive disorder gene therapy - Agilis Biotherapeutics/University of South Florida receives Orphan Drug status for Angelman syndrome in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top